PA4 inhibits CAMKIIγ kinase activity. (A) Kinase map of 17 kinases whose activities have been inhibited by ≥50% by 10 μM PA4 using in vitro kinome screening against a 371-kinase panel. (B) CAMKIIγ kinase activity after incubation with either BBM or PA4 was determined by in vitro kinase assay. The kinase activity was expressed as the percent remaining kinase activity in test samples compared with vehicle (DMSO) reactions. IC₅₀ values and curve fits were obtained using Prism (GraphPad Software). ABC, activity of bc1 complex kinase group; AGC, a group of kinases containing PKA (protein kinase A), PKG, PKC families; ALK, anaplastic lymphoma kinase; BRAF, serine/threonine-protein kinase B-raf; BTK, Bruton's tyrosine kinase; CAMK, Ca2+/calmodulin-dependent protein kinase; CK1, casein kinase 1; CMCG, cyclin-dependent kinase [CDK], mitogen-activated protein kinase [MAPK], glycogen synthase kinase [GSK3], CDC-like kinase [CLK] protein kinases group including; DAPK1, death-associated protein kinase 1; EPHA, receptor tyrosine kinase; FER, FERONI; FLT, Fms related receptor tyrosine kinase; KIT, receptor tyrosine kinase type III; PDHK, Pyruvate dehydrogenase kinase; PIKK, phosphatidylinositol 3-kinase-related kinases; PKN, serine/threonine-protein kinase N1; PRKG1, protein kinase CGMP-dependent 1; RIO, a group of kinases containing the conserved RIO (right open reading frame) domain; STE, group of kinases containing homologs of yeast sterile 7, sterile 11, sterile 20 kinases; TEK, receptor tyrosine kinase; TIF,transcriptional intermediary factor; TKL, tyrosine kinase-like.